(RTTNews) - iTeos Therapeutics, Inc. (ITOS) announced on Monday the appointment of David Feltquate as chief medical officer.
Feltquate is expected to manage the company's clinical development and regulatory strategies.
He has almost 20 years of experience in immuno-oncology clinical development, translational medicine, and the advancement of diagnostic assays. Before joining iTeos, Feltquate was the chief medical officer at Palleon Pharmaceuticals and held leadership roles at Novartis and Bristol Myers Squibb.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
